Thymosin Alpha-1 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Thymosin Alpha-1

Also known as: Tα1, Ta1, Thymalfasin, Zadaxin, TA-1, Talpha1, Tα-1, Thymosin alpha1

Endogenous thymic peptide hormone / immunomodulatory polypeptide (28 amino acids)

Research chemicalLast updated: October 31, 2026Based on 43 peer-reviewed studies

What it is

Thymosin Alpha-1 is an immune-modulating peptide widely used in other countries for hepatitis B, sepsis, cancer support, and COVID-19, though it is restricted from compounding in the USA. It works by enhancing the body's T-cell response to fight infections and cancer. Not FDA-approved; restricted from compounding; approved and used clinically in Asia and Europe.

The scientific side

Thymosin Alpha-1 (Tα1) is a 28-amino-acid endogenous peptide originally isolated from thymic tissue and processed in vivo from prothymosin alpha by a lysosomal asparaginyl endopeptidase (legumain). It functions as a biological response modifier with pleiotropic immunomodulatory activity. Tα1 acts through Toll-like receptors (TLRs), particularly TLR7, in both myeloid and plasmacytoid dendritic cells, leading to activation of downstream signaling pathways and production of immune-related cytokines. In the tumor microenvironment, Tα1 binds to phosphatidylserine on apoptotic tumor cells, is internalized by macrophages, and activates SHIP1 via TLR7/MyD88, reversing M2 polarization of tumor-associated macrophages and enhancing antitumor CD4+ and CD8+ T cell responses. Tα1 also acts as a microRNA chaperone: it binds tumor apoptotic body-borne miR-146a-5p and protects it from lysosomal RNase A degradation, enabling TLR7 activation in dendritic cells, which licenses DC maturation, migration, and tumor antigen presentation. Tα1 stimulates T-cell differentiation and proliferation, enhances thymic output as measured by T-cell receptor excision circles, and restores exhausted T cells. It suppresses myeloid-derived suppressor cells (MDSCs) via VEGF/HIF-1α downregulation and upregulates CD40/CD40-L while downregulating PDL-1/PD-1 in dendritic cell–T cell immune synapses. The peptide exhibits anti-inflammatory and antioxidant properties (PMID 30063866; PMID 31067016) and has an intrinsically disordered structure that acquires secondary structure (alpha-helix residues 14–26; double β-turns in N-terminal residues 1–12) under structure-inducing conditions (PMID 27450728; PMID 22115779).

Class: Endogenous thymic peptide hormone / immunomodulatory polypeptide (28 amino acids)

Legal & regulatory status

US FDA

As of 2023, the FDA has restricted Tα1 along with 21 additional peptides from compounding. The authors of one review characterize this restriction as 'unfounded' based on clinical trial evidence and recommend FDA permit…

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification